好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Preclinical Data for Nogo Inhibition in Stroke Recovery: A Scoping Review
Cerebrovascular Disease and Interventional Neurology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
5-026
Summarize preclinical data on Anti-Nogo-A antibodies, NgR1 decoy receptor and antagonists of Nogo/NgR1 signaling in stroke recovery and to examine whether results favor additional clinical studies in stroke.
Stroke is a leading cause of disability worldwide. While preclinical studies have shown promising results of pharmacotherapies to enhance stroke recovery, no drug has been approved for this purpose. Nogo inhibition promotes stroke recovery in animal models, and recent trials of Nogo inhibition in spinal cord injury suggest safety, tolerability, and efficacy in humans. 
Our study followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis Extension for Scoping Reviews (PRISMA-ScR) recommendations. A Pubmed search and citation searching for articles on Nogo inhibition in animal models of stroke was performed with the assistance of a librarian.
298 articles were identified. Of those, 261 were excluded based on title and abstract being non-responsive to the topic. After reviewing the full text of 37 articles, 5 additional articles were excluded, leaving 32 studies for inclusion. Experimental models of stroke, pharmacological interventions, and functional outcome assessments varied between studies. 90.6% of the studies were conducted in rodents and 9.4% in non-human primates. The most common pharmacological intervention was anti-Nogo-A antibodies (72%). Three studies combined pharmacological interventions with motor training. The forelimb grasping test was the most commonly used functional outcome test (53%). A positive treatment effect was observed in 87% of the studies.
There is substantial preclinical literature to support the benefit of Nogo inhibiton. Coupled with the existing safety data of Nogo inhibition in patients with spinal cord disease, this supports a trial of Nogo inhibition in patients recovering from ischemic stroke. Further research on Nogo inhibition would benefit from standardization of methods (e.g., dosing, time of intervention, assessment of functional outcomes) and the combined treatment with rehabilitation programs compared to pharmacological treatment alone. 
Authors/Disclosures
Jose Eduardo Espindola Lima, MD
PRESENTER 		Dr. Espindola Lima has nothing to disclose.
Sophie Rengarajan, MD, PhD (Stanford Neurology) Dr. Rengarajan has nothing to disclose.
Anna-Sophia Wahl (LMU Munich) No disclosure on file
Paul M. George, MD, PhD, MSE, FAAN (Stanford Hospital) Dr. George has received personal compensation in the range of $0-$499 for serving as a Consultant for ConductiveBio. Dr. George has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law firms. The institution of Dr. George has received research support from Conductive Bio. The institution of Dr. George has received research support from NIH. Dr. George has received intellectual property interests from a discovery or technology relating to health care. Dr. George has received personal compensation in the range of $10,000-$49,999 for serving as a Adjudicator with Baim Insititute. Dr. George has a non-compensated relationship as a Board Member with 好色先生 that is relevant to AAN interests or activities. Dr. George has a non-compensated relationship as a International Stroke Council Program committee member with American Heart Association that is relevant to AAN interests or activities.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Maarten G. Lansberg, MD (Stanford Stroke Center) Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Richard & Connor. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Keating Jones Hughes. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Chason, Rosner, Leary & Marshall. Dr. Lansberg has received publishing royalties from a publication relating to health care.